The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Anlotinib combined with TQB2450 (PD-L1 blockade) as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicenter, open-label phase Ⅱ clinical trial.
 
Xiuli Yang
Research Funding - Chia Tai Tianqing Pharmaceutical Group (Inst)
 
Xiangrui Meng
Research Funding - Chia Tai Tianqing Pharmaceutical Group (Inst)
 
Yong-Gui Hong
Research Funding - Chia Tai Tianqing Pharmaceutical Group (Inst)
 
Zhiye Zhang
Research Funding - Chia Tai Tianqing Pharmaceutical Group (Inst)
 
Jin Xia
Research Funding - Chia Tai Tianqing Pharmaceutical Group (Inst)
 
Tao Wu
Research Funding - Chia Tai Tianqing Pharmaceutical Group (Inst)
 
Yunfang Chen
Research Funding - Chia Tai Tianqing Pharmaceutical Group (Inst)
 
Zheng-Zheng Shan
Research Funding - Chia Tai Tianqing Pharmaceutical Group (Inst)
 
Qingxia Fan
Research Funding - Chia Tai Tianqing Pharmaceutical Group (Inst)
 
Feng Wang
Research Funding - Chia Tai Tianqing Pharmaceutical Group (Inst)